HHS issues contracts for pandemic vaccine research

GlaxoSmithKline has won a $63.3 million contract from Health and Human Services to develop pre-pandemic and pandemic vaccines, supporting its research into adjuvants that boost the effectiveness of vaccines. The 5-year contract also gives the U.S. Government the option to fund an additional $44 million of future clinical development programs related to antigen-sparing pandemic vaccines. Iomai, meanwhile, announced it will receive a contract from HHS to fund the development of a dose-sparing patch for use with a pandemic influenza vaccine.

A limited global supply capacity of flu antigen makes it critical that we use innovative adjuvant system technology to produce a new generation of flu pandemic vaccines," said David Stout, president of pharmaceuticals at GlaxoSmithKline.

- here's the release on GSK's contract
- and here's the release on Iomai 

Related Articles:
HHS awards H5N1 contracts. Report
Switzerland to stockpile GSK's bird flu vaccine. Report
Novartis wins $220M flu vaccine contract. Report